Cosmo Pharmaceuticals N.V. (SWX:COPN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 1.85B +82.0% |
| Revenue (ttm) | 170.24M -1.7% |
| Net Income | 56.03M +1.7% |
| EPS | 3.43 +0.1% |
| Shares Out | 15.94M |
| PE Ratio | 33.80 |
| Forward PE | 432.14 |
| Dividend | 1.88 (1.64%) |
| Ex-Dividend Date | Jun 4, 2025 |
| Volume | 26,758 |
| Average Volume | 46,640 |
| Open | 115.20 |
| Previous Close | 114.60 |
| Day's Range | 114.40 - 117.00 |
| 52-Week Range | 41.60 - 119.40 |
| Beta | 1.46 |
| RSI | 65.07 |
| Earnings Date | Mar 9, 2026 |
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive... [Read more]
News
Cosmo Pharmaceuticals Posts EUR 104 Mln Revenue, Midpoint Of 2025 Guidance Range
(RTTNews) - Cosmo Pharmaceuticals N.V. (COPN.SW,CMOPF) reported strong preliminary unaudited results for 2025, highlighting continued revenue growth and a robust cash position. The company achieved re...
Is this the end of baldness? This stock jumps 50% on breakthrough
Cosmo Pharmaceuticals (SWX: COPN) has rallied more than 50% over the past week, driven by positive results in late-stage trials … Continue reading The post Is this the end of baldness? This stock jump...
Cosmo Pharmaceuticals (CMOPF) Stock Soars on Promising Hair Loss Treatment Results
Cosmo Pharmaceuticals (CMOPF) Stock Soars on Promising Hair Loss Treatment Results
EU Grants Marketing Authorization For Winlevi Cream
(RTTNews) - Cosmo Pharmaceuticals (COPN.SW) and Glenmark Pharmaceuticals (53229) announced on Monday that they have gained approval from the European Commission for Winlevi, which is a clascoterone cr...
EU Approves Cosmo Pharma' Winlevi For Acne Treatment In Adults And Adolescents
(RTTNews) - Cosmo Pharmaceuticals N.V. (COPN.SW) announced that the European Commission has granted regulatory approval for Winlevi (clascoterone 1% cream) in the European Union. The topical treatment...
Winlevi Acne Cream Secures EU Drug Panel Support in Reversal for Cosmo
Cosmo Pharmaceuticals NV won the backing of European Union regulators for its acne treatment cream, Winlevi, after a surprise initial rejection earlier this year.
Cosmo Pharmaceuticals ernennt neuen Chief Legal Counsel
Biopharma - Der Pharmakonzern Cosmo Pharmaceuticals hat Federico Sommariva zum neuen Chief Legal Counsel ernannt.
Cosmo Pharmaceuticals reports FY results
Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ...
Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and Strategic Challenges
Full Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript
Full Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript
Cosmo Pharmaceuticals estimates 186% Y/Y growth in 2024 revenue
Cosmo Pharmaceuticals gets new finance chief
Cosmo Pharmaceuticals N.V. appoints Svetlana Sigalova as new CFO, succeeding Niall Donnelly effective November 11, 2024.